Lung Cancer CALGB 30607

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progesssing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer.